School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia.
Centre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia.
Health Expect. 2024 Dec;27(6):e70092. doi: 10.1111/hex.70092.
Medication-related problems remain a significant burden despite the availability of various interventions and services in primary care. Involving health care consumers to design interventions or services across health disciplines is becoming more widely used as this type of engagement reportedly leads to more accessible, acceptable and sustainable health services and quality of life. We conducted a scoping review to examine when and how consumers have been involved in the design and development of medication safety interventions or services within the primary care.
We searched five key databases (MEDLINE (EBSCOhost), CINAHL (EBSCOhost), PsycINFO (EBSCOhost), Embase (Elsevier) and Cochrane Library (Wiley)) for relevant articles published up to February 2024. Studies were included if they involved adult consumers (≥ 18 years), their families, carers or the wider community as stakeholders. This review only included studies where the aim was to improve safe and effective medication use, delivered exclusively in primary care. To examine consumer involvement approaches and methods we adapted a framework describing the stages of consumer involvement for the data extraction tool.
Overall, 15 studies were included (comprising 24 articles). Codesign, experience-based codesign, coproduction and participatory action research were commonly used approaches. Meetings, interviews, surveys/questionnaires were commonly used methods. Two studies reported consumer involvement across all stages of the research study, and only one study described the consumer experience of being involved in the research process. The impact of consumer involvement on the effectiveness of these services or interventions was mixed.
The potential benefits of consumer involvement in the design and development of medication safety interventions or services may not have been fully maximised, given that genuine consumer involvement across all stages of the research study appears uncommon. More transparent and consistent reporting around the description of consumers involved, their experience of being involved and overall impact and quality of consumer participation is needed.
This scoping review was undertaken without consumers, patients, service users, caregivers or people with lived experience or members of the public due to resource limitations. This scoping review was undertaken and written by academics, who have undertaken codesign with consumers and stakeholders and also have personal lived experience of medication-related problems.
尽管在初级保健中提供了各种干预措施和服务,药物相关问题仍然是一个重大负担。跨卫生学科让医疗保健消费者参与设计干预措施或服务的做法越来越普遍,因为据报道,这种参与方式可以带来更易获得、更能被接受和更可持续的卫生服务以及更高的生活质量。我们进行了一项范围综述,以调查消费者何时以及如何参与设计和开发初级保健中的药物安全干预措施或服务。
我们在五个主要数据库(MEDLINE(EBSCOhost)、CINAHL(EBSCOhost)、PsycINFO(EBSCOhost)、Embase(Elsevier)和Cochrane Library(Wiley))中搜索了截至 2024 年 2 月发表的相关文章。如果研究涉及成年消费者(≥18 岁)、他们的家人、照顾者或更广泛的社区作为利益相关者,则将其纳入研究。本综述仅包括旨在提高安全有效的药物使用的研究,这些研究仅在初级保健中进行。为了检查消费者参与方法,我们使用了一个描述消费者参与数据提取工具的各个阶段的框架来改编方法。
总体而言,纳入了 15 项研究(包括 24 篇文章)。共同设计、基于经验的共同设计、共同生产和参与式行动研究是常用的方法。会议、访谈、调查/问卷是常用的方法。有两项研究报告了在研究的所有阶段都有消费者参与,只有一项研究描述了消费者参与研究过程的体验。消费者参与对这些服务或干预措施的有效性的影响参差不齐。
鉴于在研究的所有阶段都有真正的消费者参与似乎并不常见,因此药物安全干预措施或服务的设计和开发中消费者参与的潜在好处可能尚未得到充分发挥。需要更透明和一致地报告参与的消费者、他们的参与体验以及消费者参与的整体影响和质量。
由于资源限制,这项范围综述没有让消费者、患者、服务用户、护理人员或有过药物相关问题经历的人或公众参与。这项范围综述是由学者进行的,他们与消费者和利益相关者进行了共同设计,并且个人也有药物相关问题的经历。